Adjuvant chemoradiation for gastric cancer: multicentric study of the Anatolian Society of Medical Oncology.

Autor: Kucukoner M; Anatolian Society of Medical Oncology Association (ASMO), Turkey. drmehmetonko@hotmail.com, Isikdogan A, Arpaci E, Bilici M, Uncu D, Cetin B, Dane F, Inane M, Kaplan MA, Cayir K, Yetisyigit T, Ozdemir N, Inal A, Aksoy S, Alkis N, Tekin SB, Eroglu C, Turhal S, Benekli M, Buyukberber S
Jazyk: angličtina
Zdroj: Hepato-gastroenterology [Hepatogastroenterology] 2012 Oct; Vol. 59 (119), pp. 2343-7.
DOI: 10.5754/hge11709
Abstrakt: Background/aims: The aims of this study were to report the clinical outcomes of adjuvant chemo-radiotherapy after curative resection in 637 patients with gastric cancer.
Methodology: The retrospective analysis included 637 patients with resectable gastric cancer and stage IB-IV (M0) from 8 medical centers between 2003 and 2010. The patients were treated with 5FU-leucovorin and radiotherapy according to Schema for INT-0116.
Results: Of the 637 patients, the median of overall survival (OS) was 43.7 months and relapse free survival (RFS) was 36.6 months. OS rates were 84%, 45%, 40% while RFS rates were 81%, 45% and 35% at 1, 3 and 5-years, respectively. Hematological and gastrointestinal toxicities (grade 1-4) were observed in 35% and 36.5% of patients, respectively. In univariate analysis, according to the Lauren classification, tumor grade, T stage, N stage, type of operation (total gastrectomy or subtotal) and surgery resection margin (R0 or R1) were found as prognostic factors on RFS and OS (p<0.05). In multivariate analysis, T stage, N stage and surgical margins were found as effective factors on OS. T stage, N stage and Lauren classification were factors affecting RFS.
Conclusions: Adjuvant chemo-radiotherapy after curative resection of gastric cancer was feasible, with acceptable toxicities in the Turkish population.
Databáze: MEDLINE